Alnylam Pharmaceuticals
ALNY
#378
Rank
NZ$104.76 B
Marketcap
NZ$793.01
Share price
-1.55%
Change (1 day)
85.24%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2025 : NZ$2.26 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is NZ$2.26 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2025)

Total debt by year

Year Total debt Change
2024-12-31NZ$2.29 B11.33%
2023-12-31NZ$2.06 B-0.73%
2022-12-31NZ$2.07 B42.38%
2021-12-31NZ$1.46 B102.2%
2020-12-31NZ$0.72 B60.12%
2019-12-31NZ$0.45 B908.67%
2018-12-31NZ$44.72 M5.88%
2017-12-31NZ$42.24 M-80.49%
2016-12-31NZ$0.21 B
2007-12-31NZ$8.82 M-31.97%
2006-12-31NZ$12.96 M19.86%
2005-12-31NZ$10.81 M7.21%
2004-12-31NZ$10.09 M252.89%
2003-12-31NZ$2.85 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Arrowhead Pharmaceuticals
ARWR
NZ$0.61 B-73.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
NZ$4.68 B 106.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ$2.16 B-4.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ$0.68 B-69.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ$2.42 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
NZ$55.43 B 2,347.32%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$44.19 B 1,851.26%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
NZ$29.55 B 1,204.83%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel